Reportlinker research focuses on breast cancer, lymphoma, PKI
Jun 5, 2011
Breast cancer, as well as lymphoma and protein kinase inhibitors, are the subject of a study from Reportlinker titled, "Triple Analysis."
The report provides information on breast cancer, which is the second most common type of cancer for women in the U.S., after skin cancer. Reportlinker will provide development strategies for more than 400 breast cancer drugs as well as in-depth analyses of more than 200 breast cancer drugs.
Among the topics covered by the new report is a chapter entitled "The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline?" The report will also analyze return on investment for many breast cancer therapies.
Breast cancer rates are at about one in eight women in the U.S., according to the American Cancer Society. Men are diagnosed at a rate of almost 2,000 per year. Women over the age of 40 should have yearly mammograms in order to detect breast cancer at the earliest onset. Younger women should also have regular clinical exams as well as frequent self breast-exams, to ensure that the tumors are caught as early as possible.